Characteristics of macular edema in behcet disease after intravitreal bevacizumab injection
| Autor: | Sohrab Afshari Mirak, Hormoz Chams, Farhad Shahram, Mehdi Nilli Ahmadabadi, Fariba Ghassemi, Siamak Sabour, Fereidoun Davatchi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Visual acuity genetic structures Foveal thickness Intravitreal Bevacizumab Behcet's disease Macular Edema Uveitis 03 medical and health sciences 0302 clinical medicine lcsh:Ophthalmology Ophthalmology Behcet's Disease medicine Intravitreal bevacizumab Macular edema 030203 arthritis & rheumatology medicine.diagnostic_test Behcet disease business.industry medicine.disease Fluorescein angiography eye diseases lcsh:RE1-994 030221 ophthalmology & optometry Original Article medicine.symptom business |
| Zdroj: | Journal of Ophthalmic & Vision Research, Vol 12, Iss 1, Pp 44-52 (2017) Journal of Ophthalmic & Vision Research |
| Popis: | Purpose: To investigate the effect of intravitreal bevacizumab (IVB) injection on macular edema (ME) secondary to Behcet's disease. Methods: This prospective case series included 15 patients with bilateral ME due to Behcet's disease. Intravitreal bevacizumab was injected into the more severely involved eye; the contralateral eye was evaluated as the control. Patients were followed up with comprehensive ocular examination, optical coherence tomography, and fluorescein angiography (FA) for a minimum of 6 months by a single ophthalmologist. Results: Patients with a mean age of 30.6 ± 7.4 years received a mean number of 3.3 IVB injections during the 6 months. The mean preinjection vision was 0.6 ± 0.3 and 0.4 ± 0.4 LogMAR in the case and control groups, respectively, with no significant improvement at 6 months. Mean central foveal thickness was 375.3 ± 132.1 and 307.2 ± 84.5 μm in the case and control groups, respectively, and these changed to 401 ± 199.9 (P = 0.65) and 307.7 ± 82.8 μm (P = 0.73) at month 6, respectively. A statistically nonsignificant improvement in ME was observed during the first 3 months in the case group. However, it did not persist up to month 6 on an as-needed basis. IVB injections caused a disproportionate decrease in the thickness of macular subfields. A reduction in disc leakage was observed on FA (P = 0.058). Logistic regression analysis revealed no statistically significant predictive factor for an improvement in visual acuity (VA) and a reduction in foveal thickness. Conclusion: During a 6-month period, IVB injections based on an as-needed protocol provided no statistically significant improvement in VA and ME. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|